Previous 10 | Next 10 |
home / stock / mmedf / mmedf news
OTC listed Mind Medicine ([[MMEDF]] +5.7%) has collaborated with the University Hospital Basel's Liechti Lab in a study to compare the altered states of consciousness induced by psilocybin, an active ingredient found in species of mushrooms and hallucinogenic drug, Lysergic acid die...
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – September 24, 2020 – Last year may have been all about cannabis, but it’s clear that 2020 and beyond belongs to the psychedelic medicine market. Ever since Johnson & Joh...
MindMed and Liechti Lab Announce R&D Collaboration On Psilocybin MindMed and Liechti Lab Announce R&D Collaboration On Psilocybin Canada NewsWire BASEL, Switzerland, Sept. 24, 2020 MindMed Collaborating On Study Comparing Effects Induced By LSD and Psil...
MindMed Confirms No Material Change PR Newswire NEW YORK, Sept. 23, 2020 NEW YORK , Sept. 23, 2020 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NEO: MMED)(OTCQB: MMEDF), the leading neuro-pharmaceutical company for psychedelic inspired medicines announc...
Compass Pathways’ (NASDAQ: CMPS ) recent NASDAQ debut has inspired a fellow psychedelics company to pursue a listing on the American exchange. In the wake of Compass’ successful listing on the NASDAQ last week, Mind Medicine (MindMed) (NEO: MMED ,OTCQB:MMEDF) ...
MindMed (MMEDF) has submitted an application to list its subordinate voting shares on Nasdaq.Source: Press Release For further details see: Mind Medicine plans an up-listing on Nasdaq
MindMed Submits Application For NASDAQ Up-Listing, Appoints Canaccord Genuity As Financial Advisor PR Newswire NEW YORK, Sept. 21, 2020 NEW YORK , Sept. 21, 2020 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NEO: MMED)(OTCQB: MMEDF)(DE: MMQ), the leading drug...
September 15, 2020 Palm Beach, FL – September 15, 2020 – Investors are seeing big opportunity in psychedelics based upon the numbers that the nascent cannabis industry has been putting up… after all, last year, worldwide sales of legal cannabis re-accelerated ...
Mind Medicine (MindMed) Inc. (NEO: MMED)(OTCQB: MMEDF)announced that it is working with the University Hospital Basel’s Liechti Lab on a combination MDMA and LSD in Phase 1 clinical trial. The Phase 1 MDMA-LSD trial is scheduled to start in Q4 of this year in Basel, Switzerland . ...
MindMed Announces First-Ever Clinical Trial Combining MDMA and LSD Canada NewsWire NEW YORK, Aug. 25, 2020 MindMed is funding a Phase 1 Clinical Trial at University Hospital Basel Liechti Lab NEW YORK , Aug. 25, 2020 /CNW/ -- Mind Medicine (MindMed) Inc. (NEO: MMED OT...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, June 9, 2021 /CNW/ — Mind Medicine (MindMed) Inc. (NEO: MMED)(OTC:MMEDF)(DE: BGHM) (the “Company”), a leading clinical-stage pharmaceutical company and pioneer in the field of psychedelic inspired medicines, announces that J.R. Rahn, the Com...
Last week, Deepak Chopra revealed that he’d entered into a new partnership with MindMed (NEO: MMED) (OTCQB: MMEDF), which aligned with his continued interest in mind-body healing. MindMed is a clinical-stage biotech company that is researching psychedelic medicine. In his stat...